News & Updates

In the phase III SPRINTER trial, inhaled interferon-beta-1a (IFN-β1a) showed encouraging signals for preventing disease progression or death in hospitalized COVID-19 patients.

The oral antiviral nirmatrelvir/ritonavir, but not molnupiravir, reduces the risk of hospitalization among community COVID-19 patients in Hong Kong, a real-world territory-wide retrospective cohort study has shown.

A smoking cessation intervention delivered via telephone resulted in greater smoking cessation rates than usual care among individuals enrolled in targeted lung health screening, according to results of the QuLIT*2 study from the UK presented at ERS 2022.

In the phase II TRAIL1 trial, oral pirfenidone slowed the rate of decline in lung function in individuals with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Despite being vaccinated against COVID-19, women with gout have an excess risk of developing SARS-CoV-2 infection as well as severe sequelae from it, according to a study.